Recent advances in targeted therapies in acute myeloid leukemia

RS Bhansali, KW Pratz, C Lai - Journal of Hematology & Oncology, 2023 - Springer
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

S Han, Y Liu, SJ Cai, M Qian, J Ding, M Larion… - British journal of …, 2020 - nature.com
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate
and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances …

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

P Montesinos, C Recher, S Vives… - … England Journal of …, 2022 - Mass Medical Soc
Background The combination of ivosidenib—an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

CD DiNardo, EM Stein, S de Botton… - … England Journal of …, 2018 - Mass Medical Soc
Background Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in 6 to
10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, targeted …

The significance of mitochondrial dysfunction in cancer

Y Luo, J Ma, W Lu - International journal of molecular sciences, 2020 - mdpi.com
As an essential organelle in nucleated eukaryotic cells, mitochondria play a central role in
energy metabolism, maintenance of redox balance, and regulation of apoptosis …

[HTML][HTML] An overview: the diversified role of mitochondria in cancer metabolism

Y Sun, Y Guo, X Shi, X Chen, W Feng… - … journal of biological …, 2023 - ncbi.nlm.nih.gov
Mitochondria are intracellular organelles involved in energy production, cell metabolism and
cell signaling. They are essential not only in the process of ATP synthesis, lipid metabolism …

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

EM Stein, CD DiNardo, DA Pollyea… - Blood, The Journal …, 2017 - ashpublications.org
Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in∼ 12% of patients with
acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2 …

An epigenetic role of mitochondria in cancer

Y Liu, C Chen, X Wang, Y Sun, J Zhang, J Chen, Y Shi - Cells, 2022 - mdpi.com
Mitochondria are not only the main energy supplier but are also the cell metabolic center
regulating multiple key metaborates that play pivotal roles in epigenetics regulation. These …

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

EM Stein, CD DiNardo, AT Fathi… - Blood, The Journal …, 2021 - ashpublications.org
Abstract Ivosidenib (AG-120) and enasidenib (AG-221) are targeted oral inhibitors of the
mutant isocitrate dehydrogenase (mIDH) 1 and 2 enzymes, respectively. Given their …

The emerging hallmarks of cancer metabolism

NN Pavlova, CB Thompson - Cell metabolism, 2016 - cell.com
Tumorigenesis is dependent on the reprogramming of cellular metabolism as both direct
and indirect consequence of oncogenic mutations. A common feature of cancer cell …